Lupin receives FDA OK for generic Truvada
Emtricitabine and tenofovir disoproxil fumarate tablets had a market value of roughly $2.1 billion.
Lupin has received the Food and Drug Administration’s nod for emtricitabine and tenofovir disoproxil fumarate tablets in a dosage strength of 200 mg/300 mg.
The medication is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection and for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.
The product, the generic of Gilead Sciences’ Truvada tablets, will be manufactured at the company's facility in Nagpur.
Emtricitabine and tenofovir disoproxil fumarate tablets had a market value of roughly $2.1 billion.